Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
NCT ID NCT07707947
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests the drug selumetinib in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study includes both adults and children whose tumors cannot be surgically removed or are growing. Researchers want to see if selumetinib can shrink these tumors and improve hearing, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a MEK inhibitor drug called selumetinib (Koselugo)
- What this could lead to
- If successful, selumetinib could offer a way to shrink non-surgical tumors and preserve hearing in people with NF2-related schwannomatosis.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug can cause side effects like eye and heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Drug combo aims to shrink NF2 tumors and save hearing
- AI reads MRI scans to reveal hidden brain tumor types in children before surgery
- Targeted radiation zaps childhood brain tumors in early trial
- Radiation's hidden toll on the brain: new study maps cognitive changes to protect patients